Zacks: Jounce Therapeutics Inc (JNCE) Given Consensus Rating of “” by Analysts
Jounce Therapeutics Inc (NASDAQ:JNCE) has earned a consensus broker rating score of 0.00 () from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price target of $29.00 for the company and are anticipating that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given Jounce Therapeutics an industry rank of 96 out of 265 based on the ratings given to its competitors.
JNCE has been the subject of a number of recent analyst reports. Cowen and Company initiated coverage on shares of Jounce Therapeutics in a report on Tuesday, February 21st. They set an “outperform” rating for the company. Wells Fargo & Co initiated coverage on shares of Jounce Therapeutics in a report on Tuesday, February 21st. They set an “outperform” rating for the company. They noted that the move was a valuation call. JPMorgan Chase & Co. initiated coverage on shares of Jounce Therapeutics in a report on Tuesday, February 21st. They set an “overweight” rating and a $28.00 price target for the company. Finally, Robert W. Baird initiated coverage on shares of Jounce Therapeutics in a report on Tuesday, February 21st. They set an “outperform” rating and a $30.00 price target for the company.
In related news, Director John Duncan Higgons acquired 6,700 shares of the firm’s stock in a transaction on Wednesday, February 1st. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $107,200.00. Following the acquisition, the director now owns 27,025 shares of the company’s stock, valued at $432,400. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Celgene Switzerland Llc acquired 625,000 shares of the firm’s stock in a transaction on Wednesday, February 1st. The stock was bought at an average price of $16.00 per share, with a total value of $10,000,000.00. The disclosure for this purchase can be found here.
Jounce Therapeutics (NASDAQ:JNCE) opened at 22.43 on Tuesday. The firm’s market capitalization is $54.37 million. Jounce Therapeutics has a one year low of $16.33 and a one year high of $26.31. The stock’s 50 day moving average is $20.49 and its 200-day moving average is $20.49.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Friday, March 10th. The company reported $0.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.01. The firm had revenue of $20.30 million for the quarter, compared to the consensus estimate of $15 million. The company’s quarterly revenue was up NaN% on a year-over-year basis. On average, analysts anticipate that Jounce Therapeutics will post ($0.76) EPS for the current fiscal year.
Your IP Address:
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.